Evaluación en animales del efecto protector de una inmunoglobulina anti Pseudomonas aeruginosa para uso terapéutico

Cedré, Bárbara; Fariñas, Mildrey; Callicó, Adriana; Moya, Aniel; Díaz, Dayana; Parajón, Elina; Valdés, Yolanda; Sifontes, Sergio; Infante, Juan Francisco; Izquierdo, Luis; García, Luis; Talavera, Arturo; Esnard, Sara C; Solís, Rosa L.
Vaccimonitor ; 16(1)ene.-abr. 2007. tab, graf
Artículo en Español | CUMED | ID: cum-32848

Documentos relacionados

  1. Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
  2. Reply to high cost of immunoglobulin replacement therapy: Causes and implications.
  3. After infiltration, should we administer remaining rabies immune globulin (RIG) IM? A scoping review of IM RIG for bite exposures.
  4. IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice.
  5. Amalgamation of nanotechnology with chicken IgY to enrich therapeutic and diagnostic applications: a systematic review.
  6. [Treatment of Patients with Immunodeficiency].
  7. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
  8. The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration.
  9. Convalescent Plasma Versus Hyperimmune Immunoglobulins.
  10. Blueprint for greater security of immunoglobulins for patients in Canada.